BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       
Loading...
Loading...

CP-866087 Pages on BioPortfolio:

BioPortfolio - Weight Loss
... reasons for involuntary weight loss | still s disease and arcuate ligament syndrome | CP-866087 | CP-866087 | CP 866087 | CP-866087 | CP-866 087 | . ...
http://www.bioportfolio.com/indepth/Weight_Loss.html...

Metabolic Syndrome X - B000BF02AC - Christine Kilgore
CP-866087 | CP-866 087 | metabolic syndrome X adolescents patent | . ... S T U V W X Y Z or by Most Publications, recently searched for, or most viewed. ...
http://www.bioportfolio.com/bookshop/SearchIndex/Books/Opera...

BioPortfolio - SD-6010
18.3.8 CP 866087 18.3.9 PD 332334 and CP 448187 18.3.10 SD 6010 and SC 84250 18.3.11 PF 03187207 and AG 13958 18.3.12 Zeven . ...
http://www.bioportfolio.com/search/SD-6010.html...

BioPortfolio Limited Anti-Obesity Treatments 2007 to 2012 A ...
7.1.3 Pfizer’s CP 741952 and CP 866087 7.1.4 Alizyme’s Cetilistat (ATL 962) 7.1.5 Solvay’s SLV 319 (BMS 646256) 7.1.6 Amylin’s Pramlintide (Symlin, ...
http://www.bioportfolio.com/cgi-bin/acatalog/info_309.html...

Results from other life science and pharmaceutical sites:

BioPortfolio - Weight Loss
... reasons for involuntary weight loss | still s disease and arcuate ligament syndrome | CP-866087 | CP-866087 | CP 866087 | CP-866087 | CP-866 087 | . ...
http://www.bioportfolio.com/indepth/Weight_Loss.html...

BioMed Central | Full text | Patent alert
Pfizer currently has two agents in clinical development for the treatment of obesity: PF-2575799, which entered phase I studies in early 2008, and CP-866087 ...
http://www.biomedcentral.com/1472-4472/9/684...

Blockbuster Drugs Create, Develop and Market a Billion Dollar Drug ...
18.3.8 CP 866087 18.3.9 PD 332334 and CP 448187 18.3.10 SD 6010 and SC 84250 18.3.11 PF 03187207 and AG 13958 18.3.12 Zeven 18.3.13 Influenza Vaccine ...
http://www.bioportfolio.com/cgi-bin/acatalog/info_984.html...

Patent alert
which entered phase I studies in early 2008, and CP-866087. is in phase II studies but has previously been developed. for other indications, suggesting that ...
http://www.biomedcentral.com/content/pdf/cd-921639.pdf...

CURRICULUM VITAE Raymond F. Anton, Jr., M.D. MAILING ADDRESS ...
Three Doses of CP-866087 and Naltrexone on Acute Alcohol Consumption and Carving after. Seven Days of Treatment in Alcohol Dependent (DSM-IV) Subjects who ...
http://www.musc.edu/psychiatry/faculty/fac_cv/AntonCV.pdf...

Google Custom Search

Search
  

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

BioPortfolio logo